Bridgewater-based Insmed Inc., a biopharmaceutical firm targeting serious and rare diseases, announced Thursday it has appointed Roger Adsett as its chief operating officer, effective immediately.
Adsett, who most recently served as the company’s chief commercial officer, will be responsible for those duties as well as Insmed’s overall business operations.
He will report to Will Lewis, CEO and chairman of the board.
” I am also excited to expand the responsibilities of Roger Adsett through his appointment to the newly created role of chief operating officer. Roger has shown tremendous leadership during our first year of commercial launch in the U.S. while also leading the effort to establish the key elements of our global infrastructure. In his new role, he will now be able to direct on a comprehensive basis the advancement of ARIKAYCE and our pipeline products through development, and potential approval and commercial launch in all regions,” Lewis said.
The company also promoted Drayton Wise to senior vice president, head of United States.